FRINK Linked Data Fragments server

Matches in SemOpenAlex for { <https://semopenalex.org/work/W2926613039> ?p ?o ?g. }

• W2926613039 endingPage "e190484" @default.
• W2926613039 startingPage "e190484" @default.
• W2926613039 abstract "<h3>Importance</h3> Surgery currently offers the only chance for a cure in pancreatic ductal adenocarcinoma (PDAC), but it carries a significant morbidity and mortality risk and results in varying oncologic outcomes. At present, to our knowledge, there are no tests available before surgical resection to identify tumors with an aggressive biological phenotype that could guide personalized treatment strategies. <h3>Objective</h3> Identification of noninvasive genetic biomarkers that could direct therapy in patients whose cases are amenable to pancreatic cancer resection. <h3>Design, Setting, and Participants</h3> This multicenter study combined a prospective European cohort of patients with PDAC who underwent pancreatic resection (from University Hospital of Zurich, Zurich, Switzerland; Cantonal Hospital of Winterthur, Winterthur, Switzerland; and University Clinic of Ulm, Ulm, Germany) with data from the Cancer Genome Atlas database in the United States, which includes prospectively registered patients with PDAC. A genome-wide screening for functional single-nucleotide polymorphisms (SNPs) that affect PDAC survival was conducted using the European cohort for identification and the Cancer Genome Atlas cohort for validation. We used Cox proportional hazards models to screen for high-frequency polymorphic variants that are associated with allelic differences in tumor-associated survival and either result in an altered protein structure and function or reside in known regulatory noncoding genomic regions. The false-discovery rate method was applied for multiple hypothesis-testing corrections. Data analysis occurred from November 2017 to May 2018. <h3>Exposures</h3> Pancreatic resection. <h3>Main Outcomes and Measures</h3> Tumor-associated survival. <h3>Results</h3> A total of 195 patients in the European cohort were included, as well as 136 patients in the Cancer Genome Atlas cohort (overall median [range] age, 66 [19-87] years; 156 [47.1%] were women, and 175 [52.9%] were men). Two SNPs in noncoding, functional regions of genes that regulate cancer progression, invasion, and metastasis were identified (<i>CHI3L2</i>SNPrs684559and<i>CD44</i>SNPrs353630). These were associated with survival after PDAC resection; patients who carry the risk alleles at 1 of both SNP loci had a 2.63-fold increased risk for tumor-associated death compared with those with protective genotypes (hazard ratio for survival, 0.38 [95% CI, 0.27-0.53];<i>P</i> = 1.0 × 10⁻⁸). <h3>Conclusions and Relevance</h3> The identified polymorphisms may serve as a noninvasive biomarker signature of prospective survival after pancreatic resection that is readily available at the time of PDAC diagnosis. This signature can be used to identify a subset of high-risk patients with PDAC with very low survival probability who might be eligible for inclusion in clinical trials of new therapeutic strategies, including neoadjuvant chemotherapy protocols. In addition, the biological knowledge about these SNPs could help guide the development of individualized genomic strategies for PDAC therapies." @default.
• W2926613039 created "2019-04-11" @default.
• W2926613039 creator A5000743292 @default.
• W2926613039 creator A5004992476 @default.
• W2926613039 creator A5011732266 @default.
• W2926613039 creator A5019003350 @default.
• W2926613039 creator A5024948228 @default.
• W2926613039 creator A5029760404 @default.
• W2926613039 creator A5035497488 @default.
• W2926613039 creator A5036543235 @default.
• W2926613039 creator A5037978981 @default.
• W2926613039 creator A5045791302 @default.
• W2926613039 creator A5050751065 @default.
• W2926613039 creator A5051235246 @default.
• W2926613039 creator A5053110552 @default.
• W2926613039 creator A5075437310 @default.
• W2926613039 date "2019-06-19" @default.
• W2926613039 modified "2023-10-18" @default.
• W2926613039 title "Identification and Validation of a Biomarker Signature in Patients With Resectable Pancreatic Cancer via Genome-Wide Screening for Functional Genetic Variants" @default.
• W2926613039 cites W1990127663 @default.
• W2926613039 cites W1991708979 @default.
• W2926613039 cites W2004935845 @default.
• W2926613039 cites W2018046598 @default.
• W2926613039 cites W2019264784 @default.
• W2926613039 cites W2023623233 @default.
• W2926613039 cites W2026362825 @default.
• W2926613039 cites W2027072680 @default.
• W2926613039 cites W2037632318 @default.
• W2926613039 cites W2042570199 @default.
• W2926613039 cites W2050565528 @default.
• W2926613039 cites W2059145105 @default.
• W2926613039 cites W2063475603 @default.
• W2926613039 cites W2066185056 @default.
• W2926613039 cites W2074498980 @default.
• W2926613039 cites W2076154138 @default.
• W2926613039 cites W2081872599 @default.
• W2926613039 cites W2088181957 @default.
• W2926613039 cites W2091091750 @default.
• W2926613039 cites W2102659607 @default.
• W2926613039 cites W2104549677 @default.
• W2926613039 cites W2114954919 @default.
• W2926613039 cites W2118075248 @default.
• W2926613039 cites W2118705337 @default.
• W2926613039 cites W2131204916 @default.
• W2926613039 cites W2132888849 @default.
• W2926613039 cites W2134378807 @default.
• W2926613039 cites W2141531534 @default.
• W2926613039 cites W2150534538 @default.
• W2926613039 cites W2151447617 @default.
• W2926613039 cites W2152553903 @default.
• W2926613039 cites W2158387167 @default.
• W2926613039 cites W2159057646 @default.
• W2926613039 cites W2166320441 @default.
• W2926613039 cites W2168942492 @default.
• W2926613039 cites W2226913284 @default.
• W2926613039 cites W2259938310 @default.
• W2926613039 cites W2269849065 @default.
• W2926613039 cites W2409734963 @default.
• W2926613039 cites W2409865497 @default.
• W2926613039 cites W2417483443 @default.
• W2926613039 cites W2481864155 @default.
• W2926613039 cites W2611688186 @default.
• W2926613039 cites W2748710555 @default.
• W2926613039 cites W2769055045 @default.
• W2926613039 cites W2770835903 @default.
• W2926613039 cites W2785043177 @default.
• W2926613039 cites W2912196744 @default.
• W2926613039 cites W4229719081 @default.
• W2926613039 cites W4254377425 @default.
• W2926613039 cites W4254814767 @default.
• W2926613039 doi "https://doi.org/10.1001/jamasurg.2019.0484" @default.
• W2926613039 hasPubMedCentralId "https://www.ncbi.nlm.nih.gov/pmc/articles/6583393" @default.
• W2926613039 hasPubMedId "https://pubmed.ncbi.nlm.nih.gov/30942874" @default.
• W2926613039 hasPublicationYear "2019" @default.
• W2926613039 type Work @default.
• W2926613039 sameAs 2926613039 @default.
• W2926613039 citedByCount "22" @default.
• W2926613039 countsByYear W29266130392019 @default.
• W2926613039 countsByYear W29266130392020 @default.
• W2926613039 countsByYear W29266130392021 @default.
• W2926613039 countsByYear W29266130392022 @default.
• W2926613039 countsByYear W29266130392023 @default.
• W2926613039 crossrefType "journal-article" @default.
• W2926613039 hasAuthorship W2926613039A5000743292 @default.
• W2926613039 hasAuthorship W2926613039A5004992476 @default.
• W2926613039 hasAuthorship W2926613039A5011732266 @default.
• W2926613039 hasAuthorship W2926613039A5019003350 @default.
• W2926613039 hasAuthorship W2926613039A5024948228 @default.
• W2926613039 hasAuthorship W2926613039A5029760404 @default.
• W2926613039 hasAuthorship W2926613039A5035497488 @default.
• W2926613039 hasAuthorship W2926613039A5036543235 @default.
• W2926613039 hasAuthorship W2926613039A5037978981 @default.
• W2926613039 hasAuthorship W2926613039A5045791302 @default.
• W2926613039 hasAuthorship W2926613039A5050751065 @default.
• W2926613039 hasAuthorship W2926613039A5051235246 @default.
• W2926613039 hasAuthorship W2926613039A5053110552 @default.
• W2926613039 hasAuthorship W2926613039A5075437310 @default.
• W2926613039 hasBestOaLocation W29266130392 @default.

• next